On Jun 29, 2018 Ziopharm Oncology Inc (NASDAQ:ZIOP) Shorts Strengthened By 0.09%

June 29, 2018 - By Madeline Delgado

It was registered an increase on Ziopharm Oncology Inc (NASDAQ:ZIOP)’s shorted shares with 0.09%. In June was published ZIOP’s total 35.65 million shorted shares by FINRA. The up change of 0.09% from 35.62 million shares was reported. Previous ZIOP’s position will need 48 days to recover. It has 751,200 average volume. Ziopharm Oncology Inc float short is 32.78%.

Ticker’s shares touched $3.01 during the last trading session after 1.95% change.ZIOPHARM Oncology, Inc. has volume of 572,478 shares. Since June 29, 2017 ZIOP has declined 31.35% and is downtrending. ZIOP underperformed the S&P 500 by 43.92%.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology.The firm is valued at $424.01 million. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon??s synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 evaluated for the treatment of metastatic melanoma, unresectable recurrent or metastatic breast cancer, and Grade III malignant glioma .Last it reported negative earnings. The Company’s synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Ratings Coverage

In total 2 analysts cover Ziopharm Oncology (NASDAQ:ZIOP). “Buy” rating has 1, “Sell” are 1, while 0 are “Hold”. 50% are bullish. 3 are the (NASDAQ:ZIOP)’s analyst reports since March 5, 2018 according to StockzIntelligence Inc. On Monday, March 5 H.C. Wainwright maintained ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) rating. H.C. Wainwright has “Buy” rating and $9.5 target. On Monday, May 14 the rating was maintained by H.C. Wainwright with “Buy”. In Monday, June 18 report JP Morgan downgraded the stock to “Underweight” rating.

For more ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) news announced recently go to: Nasdaq.com, Streetinsider.com, Streetinsider.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Mid-Afternoon Market Update: Crude Oil Up Over 1%; Gevo Shares Spike Higher” announced on June 18, 2018, “Pre-Open Movers 06/18: (PTCT) (CBPO) (RCII) Higher; (CBIO) (ZIOP) (RDFN) Lower (more…)” on June 18, 2018, “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” with a publish date: June 28, 2018, “Investor Expectations to Drive Momentum within ZIOPHARM Oncology, MedEquities Realty Trust, Argan, Churchill …” and the last “Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19 …” with publication date: June 18, 2018.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: